Overview

A Study to Investigate if Long Acting Cabotegravir (CAB) and Lenacapavir (LEN) Injections Are Tolerable and Acceptable When Administered to Healthy Adults Without HIV

Status:
ACTIVE_NOT_RECRUITING

Trial end date:
2026-07-10

Target enrollment:

Participant gender:

Summary

This study will evaluate the tolerability and acceptability of injection site reactions (ISRs) of two long-acting (LA) injectables. Additional characteristics of the ISRs will be investigated and described as well as safety outcomes.

Phase:

PHASE1

Details

Lead Sponsor:

ViiV Healthcare

Treatments:

cabotegravir